PT  - JOURNAL ARTICLE
AU  - Binh T. Ngo
AU  - Paul Marik
AU  - Pierre Kory
AU  - Leland Shapiro
AU  - Denise Brennan-Rieder
AU  - Raphael Thomadsen
AU  - Jose Iglesias
AU  - Stephen Ditmore
AU  - Marc Rendell
AU  - Joseph Varon
AU  - Michael Dubé
AU  - Neha Nanda
AU  - Gino In
AU  - Daniel Arkfeld
AU  - Preet Chaudhary
AU  - Vito M. Campese
AU  - Diana L. Hanna
AU  - David E. Sawcer
AU  - Glenn Ehresmann
AU  - David Peng
AU  - Miroslaw Smogorewski
AU  - April Armstrong
AU  - Rajkumar Dasgupta
AU  - Fred Sattler
AU  - Cristina Mussini
AU  - Oriol Mitja
AU  - Vicente Soriano
AU  - Nicolas Peschanski
AU  - Gilles Hayem
AU  - Marco Confalonieri
AU  - Maria Carmela Piccirillo
AU  - Antonio Lobo-Ferreira
AU  - Iraldo Bello Rivero
AU  - Eivind H. Vinjevoll
AU  - Daniel Griffin
AU  - Ivan FN Hung
TI  - The Time Course of Therapeutic Interventions for Covid-19
AID  - 10.1101/2020.05.27.20115238
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.27.20115238
4099  - http://medrxiv.org/content/early/2020/11/07/2020.05.27.20115238.short
4100  - http://medrxiv.org/content/early/2020/11/07/2020.05.27.20115238.full
AB  - BACKGROUND The spread of COVID-19 from Wuhan China, has been alarmingly rapid. Epidemiologic techniques succeeded in containing the disease in China, but efforts have not been as successful in the rest of the World. As of November 1, 2020, there have been 45,942,902 confirmed cases of COVID-19, resulting in 1,192,644 deaths worldwide. Projections are for continued new infections and deaths if no effective therapeutic interventions can be initiated over the next several months. We performed a systematic review to determine the potential time course for development of treatments and vaccines, focusing on availability now and by year end 2020.Clinical Trials We reviewed up-to-date information from several sources to identify potential treatments for COVID-19: The Reagan-Udall Expanded Access Navigator COVID-19 Treatment Hub was used to track the efforts of companies to develop agents. We focused on trials completed as of September 15, 2020 on identified agents We used several different sources: (A) covid-trials.org, then validated results on (B) clinicaltrials.gov and the (C) World Health Organization’s International Clinical Trials Registry Platform (WHO ICTRP). We excluded studies which were clearly observational, with no randomization, control, or comparison group. We further set a cutoff of 100 for numbers of subjects, since smaller trial size could lack statistical power to establish superiority of the intervention over the control.Publications We searched for all published trial results on pubmed.gov and on medRxiv, the preprint server, and used a targeted Google™ search to find announcements of unpublished trial resultsClinical Trials in Recruitment We identified 663 trials currently in recruitment phase with subject size of 100 or more. Of these, 108 were directed at prevention in healthy individuals, 82 were classified as treatment of outpatients with documented infection, and 330 were for treatment of hospitalized inpatients.Clinical trials Completed As of November 15, 2020, there were only 80 studies with 100 or more subjects, including ; 49 trials in hospitalized patients, 9 directed at outpatients, and 10 prevention studies,Published Data As of November 1, 2020 we found 82 publications reporting findings in human studies on 12 classes of agents, and on 7 vaccines (See TABLE 2). There were 44 randomized or active controlled studies. The rest were retrospective observational analyses. Only 14 publications dealt with out-patient care, including 7 vaccine reports; the rest were all in hospitalized patients.Available Treatments At this time, remdesivir and convalescent plasma have been granted emergency use authorization in the U.S.A., solely for hospitalized patients. There is also support for glucocorticoid treatment of the COVID-19 respiratory distress syndrome. No treatments or prophylaxis are offered for outpatients.CONCLUSION COVID-19 is propagated primarily by infected ambulatory individuals. There have been no options brought forward for prevention and non-hospital treatment with only a few randomized, controlled outpatient studies expected to yield results in time to impact on the continuing pan demic by the end of 2020. It will be necessary for public health authorities to make hard decisions, with limited data, to prevent the continued spread of the disease. The choices will be hardest when dealing with possible early release of safe and effective vaccines which would, of course, be of greatest benefit to the World’s population.Competing Interest StatementDr. Binh Ngo is a speaker for Castle Biosciences. Dr. Armstrong reports grants and personal fees from Abbvie, grants and personal fees from Bristol-Myers Squibb, personal fees from Dermavant, grants from Dermira, grants and personal fees from Eli Lilly, grants and personal fees from Janssen, grants from Kyowa Hakko Kirin, grants and personal fees from LEO Pharma, grants and personal fees from Modernizing Medicine, grants and personal fees from Novartis, personal fees from Ortho-Dermatologics, personal fees from Pfizer, grants and personal fees from Regeneron, personal fees from Sanofi-Genzyme, personal fees from Science 37, Inc, grants from UCB Biopharma Dr. Dube reports grants from Gilead Sciences, outside the submitted work; Dr. Chaudhary has held stock in Gilead Sciences, Roche Holding and Moderna. Dr. Piccirillo reports personal fees from Daichii Sankyo, personal fees from GSK, personal fees from MSD, grants from Roche, grants and personal fees from AstraZeneca, non-financial support from Bayer, outside the submitted work; . Dr. Mussini is member of a Roche Data Safety Monitoring Board for tocilizumab Funding StatementNo external fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB needed for systematic analysisAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe have provided a comprehensive list of all clinical trials with their registration as Supplementary Table 1 https://www.covid-trials.org/ https://clinicaltrials.gov/ https://www.who.int/ictrp/en/ https://reaganudall.org/covid-19